(RTTNews) - Glaukos Corp. (GKOS) on Wednesday reported three-year results from a Phase 3 extension study evaluating Epioxa, its epithelium-on corneal cross-linking therapy for keratoconus.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.